RecombinantFGF-8e, Human

• Description:

  Fibroblast Growth Factor 8e (FGF-8e) is a cytokine belonging to the heparin-binding FGF family, which has at least 23 members. FGF-8 has 8 different isoforms, named FGF-8a through FGF-8h. Different FGF-8 isoforms have different receptor affinities, and thus participate in different signaling cascade pathways. FGF-8 has widespread expression during embryonic development, promoting gastrulation, somitogenesis, morphogenesis, and limb formation. FGF-8 also has oncogenic potential. While in normal cells FGF-8 is expressed at very low levels, in breast, prostate and ovarian cancer FGF-8 is highly expressed.FGF-8 promotes tumor angiogenesis by increasing neovascularization, and inducing osteoblastic differentiation. Recombinant Human FGF-8e produced in E.coli is a single non-glycosylated polypeptide chain containing 212 amino acids. A fully biologically active molecule, rhFGF-8e has a molecular mass of 24.3 kDa analyzed by reducing SDS-PAGE and is obtained by chromatographic techniques at GenScript.

• Endotoxin:

  < 0.2 EU/μg, determined by LAL method.

• Purity:

  > 95% as analyzed by SDS-PAGE

• Bioactivity:

  ED50 < 2.5µg/ml in the presence of 1 µg/mL heparin, measured in a cell proliferation assay using 3T3.

• Reconstitution:

  Reconstituted in ddH2O or PBS at 100 μg/ml.

• Molecular Weight:

  24.3 kDa, observed by reducing SDS-PAGE.

• Storage Conditions:

  Lyophilized recombinant Human FGF 8e remains stable up to 6 months at -80°C from date of receipt. Upon reconstitution, Human FGF 8e should be stable up to 1 week at 4°C or up to 3 months at -20°C.

• Appearance:

  Sterile Filtered White lyophilized (freeze-dried) powder.

• Formulation:

  Lyophilized after extensive dialysis against PBS.

• Host or Source:

  Escherichia coli.

• Recommended Usage:

  This material is offered by USA Bioworld biotech for research, laboratory or further evaluation purposes. For research use only.

• CAS Number:

  9000-83-3

• AA Sequence:

  MQEGPGRGPA LGRELASLFR AGREPQGVSQ QHVREQSLVT DQLSRRLIRT YQLYSRTSGK HVQVLANKRI NAMAEDGDPF AKLIVETDTF GSRVRVRGAE TGLYICMNKK GKLIAKSNGK GKDCVFTEIV LENNYTALQN AKYEGWYMAF TRKGRPRKGS KTRQHQREVH FMKRLPRGHH TTEQSLRFEF LNYPPFTRSL RGSQRTWAPE PR